This week, the FDA warns of real Viagra in supposedly all natural supplements, a survey finds less than half of adults polled in Japan had sex in the last month, and we theorize about what method of contraception was available to the ladies of Downton Abbey.
On Friday, Melissa White, the CEO of an online condom retailer, attacked the findings of a study that found a small number of the condoms she sells on her website contain a chemical carcinogen called nitrosamines. In doing so, she misrepresents both our report and its conclusions.
A new petition calls on the FDA to “Get Carcinogens Out of Condoms.” But there is no scientific evidence linking condoms to cancer—and to claim otherwise has the potential to unravel decades of committed work focused on saving lives through encouraging condom use and education.
Unfortunately, Nicholas Kristof’s great op-ed on teenage pregnancy in the New York Times last week included a misleading statistic that suggests people who rely on condoms for pregnancy prevention will eventually, inevitably become pregnant.
Many women know more about the risks of birth control than about how the right contraceptive might improve their lives.
The two-week meeting in the Vatican inspired optimism about the Catholic Church’s future teachings, but in the end, it was “much ado about nothing.”
Conservative commentators are teeing off at an ad campaign depicting a world in which birth control is banned and condoms are in short supply.
This week, new estimates suggest almost two million cases of chlamydia, there’s more evidence that HIV therapy cannot eradicate the virus in babies, and a study finds that less pubic hair may mean fewer pubic lice—though they won’t be extinct any time soon.
This week, there are new recommendations for chlamydia and gonorrhea screening for young women, a secret shopper study found that young men may have a harder time buying EC over the counter, and Kansas seizes sex toys.
For women in countries and communities with limited contraceptive choices and high rates of HIV, particularly in sub-Saharan Africa, a shortage of funding for the ECHO (Evidence for Contraceptive Options and HIV Outcomes) trial is an unacceptable development.